CANCER IN NIGERIA
As an oncologist, cancer is the main focus of my clinical, teaching and research activities. The commonest cancers in Ngeria are, among females, breast and cervical cancers, and among males, liver and prostate cancers. For more go to the Cancer page (see the side panel)
BREAST CANCER CLINICAL TRIALS IN NIGERIA
An important way of generating new knowledge about cancer treatment is the clinical trials mechanism (http://www.cancer.gov/clinicaltrials/learning/page3). Clinical trials benefit patients and institutions in many ways including:
- Providing patients access to cutting edge treatment that is often not yet widely available
- Close and detailed follow-up
- Subsidizing treatment of patients
- Contribution to new knowledge that will benefit future generation
- Working with leading experts in the field and increasing local skills and expertise
At the Oncology Division of the Department of Surgery, University College Hospital, Ibadan, patients can enroll in any of the following clinical trials:
a. An International Breast Cancer Study Group (http://www.ibcsg.org/) clinical trial of the value of metronomic chemotherapy in the treatment of breast cancer patients whose tumors are hormone receptor negative (IBCSG Trial 22-00). The chemotherapy is used as an anti-angionesis agent in these patients for whom there is currently little evidence based gold standard treatment. Patient accrual into this study will start shortly so contact us if you are a clinician interested in referring patients or you are a Nigerian patient interested in participating in the trial.
b. An International Breast Cancer Study Group (http://www.ibcsg.org/) clinical trial of chemotherapy in the treatment of breast cancer patients whose tumors have recurred after initial treatment (IBCSG Trial 27-02, NSABP Protocol B37, BIG Trial 1-02). There is currently no gold standard for the treatment of these patients and studies like this will help us to know what to do for cush patients in future. Patient accrual into this study will start shortly so contact us if you are a clinician interested in referring patients or you are a Nigerian patient interested in participating in the trial.
We have published our analysis of the molecular subtype of breast cancer seen in Ibadan and contrary to the often stated claims, there was no substantial difference in the pattern compared to the results from well conducted studies from other parts of the world. This finding is practice changing in many ways:
a. When the ER/PR status of patients is unknown, it is appropriate to treat as ER positive
b. We need to focus on other issues such as quality of care, early presentation, etc to reduce the poor survival of our breast cancer patients rather than assume that it is due to biology.